Roka Bioscience, Inc., a Warren, NJ-based company that focuses on developing and commercializing innovative solutions based on molecular technologies for the industrial markets, has completed a $20m Series C equity financing.
Investors include OrbiMed Advisors, New Enterprise Associates, Inc., TPG Biotech and Gen-Probe Incorporated (NASDAQ: GPRO).
The financing brings the total amount raised by the company to date to $57.2m.
Founded in September 2009 through a spin-off of Gen-Probe’s industrial testing assets and technology, and led by CEO and President Paul Thomas, Roka Bioscience focuses on developing highly accurate molecular assays for food safety testing and other industrial applications. Its nucleic acid tests will be based on proven technologies and instrument platforms with exclusive licensing rights from Gen-Probe.
Eighteen former Gen-Probe employees with expertise in industrial fields joined Roka at the time of the spin-off. Today the company has 75 employees and operates a California office in San Diego.